Inflammatory Breast Cancer and Transient Complete Radiographic Response to Chemoimmunotherapy: A Case Report.

ABSTRACT:

Introduction

Inflammatory breast cancer is a rare and aggressive subtype, with high breast cancer mortality. Compared to noninflammatory breast cancer, even after treatment and response to standard-of-care breast cancer chemotherapy, it has a high propensity for lymph node involvement, high rates of distant metastasis, and shorter survival. The immune checkpoint inhibitor, pembrolizumab, in combination with chemotherapy is now approved for early triple negative breast cancer (TNBC) and for advanced disease if positive for the programmed cell death ligand 1 protein (PD-L1). The response and survival of metastatic inflammatory TNBC to immunotherapy is largely unreported and we present a case of a young woman with metastatic triple negative inflammatory breast cancer, treated with pem

SUBMITTER: Amin A 

PROVIDER: S-EPMC11521518 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature